Cell Systems News — ACBRI 376
Transporting therapeutic drugs and agents across the blood-brain barrier (BBB) has always been a challenge for brain disease therapy. This study examines the permeability of 2D graphene nanosheets through the BBB using a popular in vitro BBB monolayer model constructed with Cell Systems primary human brain microvascular endothelial cells or hBMECs (Cat# ACBRI 376).
Research on the COVID-19 virus is uncovering the virus may, in some cases, be attacking endothelial cells and potentially causing systemic inflammation. This paper titled "Altered COVID-19 receptor ACE2 expression in a higher risk group for cerebrovascular disease and ischemic stroke" showcases research that utilized our human primary brain microvascular endothelial cells (ACBRI 376). Cell Systems offers a wide variety of human primary endothelial cells that are isolated without the use of antibodies. Our cells are more biologically relevant and offer outstanding consistency and quality for your research programs. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256621/pdf/main.pdf #endothelialcells #covid19 #coronavirus #cellsystems
In gene therapy and pharmacology, the blood brain barrier (BBB) is a known obstacle prohibiting efficient drug transport to the CNS. One step to unlocking this black box is the creation of an in vitro human BBB model. In the link below, read on to see how scientists used ACBRI 376 cells (Primary Human Brain Microvascular Endothelial Cells) to create a 3D vascular model of CNS angiogenesis. Cell Systems antibody free Primary Human Brain Microvascular Endothelial Cells are ideal tools for your cell biology research. Cell Systems ships globally from an inventory that allows for primary cells to always be...